Tracking Cathie Wood: Heavy Buying in AI Innovators and Crypto Ecosystem, Strategic Reduction in Chinese E-commerce Giant

U.S. markets closed mixed on Friday with minimal directional conviction. The S&P 500 closed at 7354.02, down 0.05%; the Nasdaq finished at 25297.62, declining 0.24%; and the Dow Jones ended at 51876.11, falling 0.09%. Investors remained cautious amid lack of clear market catalysts.

Symbols

Cathie Wood's trading strategy displayed a clear "quality over quantity" approach, substantially increasing positions in AI and biotech innovators while strategically reducing exposure to certain traditional tech names, reinforcing her commitment to disruptive innovation themes.

Buy: Concentrated Bets on AI-Powered Biotech and Crypto Infrastructure

Deep Analysis: ARK's largest position addition was $Recursion Pharmaceuticals (RXRX.US)$ with 609,643 shares, a pioneer in AI-driven drug discovery that leverages machine learning to dramatically accelerate pharmaceutical development timelines. The fund also increased its stake in $Generate Biomedicines (GENB.US)$ by 63,768 shares, a company focused on using generative AI to design novel protein therapeutics. These moves underscore ARK's conviction in the convergence of artificial intelligence and biotechnology.

In the crypto ecosystem, ARK simultaneously added to $Circle (CRCL.US)$ (+78,756 shares), $Coinbase (COIN.US)$ (+68,366 shares), and $Bullish (BLSH.US)$ (+57,511 shares), signaling strategic positioning in digital asset infrastructure. Additional purchases included $X-Energy (XE.US)$ (+67,562 shares) and $SpaceX (SPCX.US)$ (+45,728 shares), continuing the fund's long-term thesis on clean energy and space exploration.

Sell: Portfolio Rebalancing in Traditional Tech

Deep Analysis: ARK significantly reduced its position in $Alibaba (BABA.US)$ by 570,391 shares, potentially reflecting concerns about slowing growth in Chinese e-commerce and capital reallocation toward more disruptive innovation opportunities. The fund also trimmed positions in $Absci Corp (ABSI.US)$ (-192,617 shares) and $Strata Critical Medical (SRTA.US)$ (-128,350 shares), possibly for portfolio balancing purposes to free up capital for new investment opportunities. The reduction in $Roku Inc (ROKU.US)$ (-44,898 shares) may relate to intensifying competition in the streaming media landscape.

Not sure what to buy? Let the concentrated portfolios of top investors be your guide. This page aggregates high-conviction ideas from the world's best.

432K Views